UK markets close in 7 hours 24 minutes

Prelude Therapeutics Incorporated (PRLD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.63+0.01 (+0.18%)
At close: 04:00PM EDT
5.63 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 319.64M
Enterprise value 103.59M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.35
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.79

Trading information

Stock price history

Beta (5Y monthly) 1.50
52-week change 3-22.24%
S&P500 52-week change 321.83%
52-week high 38.44
52-week low 31.66
50-day moving average 34.26
200-day moving average 33.65

Share statistics

Avg vol (3-month) 368.21k
Avg vol (10-day) 339.68k
Shares outstanding 542.07M
Implied shares outstanding 654.92M
Float 813.62M
% held by insiders 16.93%
% held by institutions 173.74%
Shares short (28 Mar 2024) 4621.86k
Short ratio (28 Mar 2024) 412.8
Short % of float (28 Mar 2024) 44.68%
Short % of shares outstanding (28 Mar 2024) 41.13%
Shares short (prior month 29 Feb 2024) 4619.09k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-33.19%
Return on equity (ttm)-56.33%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -131.11M
Net income avi to common (ttm)-121.83M
Diluted EPS (ttm)-2.02
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)232.94M
Total cash per share (mrq)4.24
Total debt (mrq)16.89M
Total debt/equity (mrq)7.12%
Current ratio (mrq)10.79
Book value per share (mrq)4.32

Cash flow statement

Operating cash flow (ttm)-107.06M
Levered free cash flow (ttm)-58.93M